A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

NCT03254927 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision based on emerging risk-benefit profile

Conditions

Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: CDX-3379 and cetuximab

Sponsor

Celldex Therapeutics